These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 31861948)

  • 1. The Thrombopoietin Receptor Agonist Eltrombopag Inhibits Human Cytomegalovirus Replication Via Iron Chelation.
    Vogel JU; Schmidt S; Schmidt D; Rothweiler F; Koch B; Baer P; Rabenau H; Michel D; Stamminger T; Michaelis M; Cinatl J
    Cells; 2019 Dec; 9(1):. PubMed ID: 31861948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eltrombopag inhibits the proliferation of Ewing sarcoma cells via iron chelation and impaired DNA replication.
    Waters T; Goss KL; Koppenhafer SL; Terry WW; Gordon DJ
    BMC Cancer; 2020 Nov; 20(1):1171. PubMed ID: 33256675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An in silico-designed flavone derivative, 6-fluoro-4'-hydroxy-3',5'-dimetoxyflavone, has a greater anti-human cytomegalovirus effect than ganciclovir in infected cells.
    Fujimoto KJ; Nema D; Ninomiya M; Koketsu M; Sadanari H; Takemoto M; Daikoku T; Murayama T
    Antiviral Res; 2018 Jun; 154():10-16. PubMed ID: 29559264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombopoietin receptor-independent stimulation of hematopoietic stem cells by eltrombopag.
    Kao YR; Chen J; Narayanagari SR; Todorova TI; Aivalioti MM; Ferreira M; Ramos PM; Pallaud C; Mantzaris I; Shastri A; Bussel JB; Verma A; Steidl U; Will B
    Sci Transl Med; 2018 Sep; 10(458):. PubMed ID: 30209246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic effects by combination of ganciclovir and tricin on human cytomegalovirus replication in vitro.
    Yamada R; Suda H; Sadanari H; Matsubara K; Tuchida Y; Murayama T
    Antiviral Res; 2016 Jan; 125():79-83. PubMed ID: 26640224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Iron Chelation in Osteosarcoma.
    Argenziano M; Di Paola A; Tortora C; Di Pinto D; Pota E; Di Martino M; Perrotta S; Rossi F; Punzo F
    Curr Cancer Drug Targets; 2021; 21(5):443-455. PubMed ID: 33380300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia.
    Guan Y; Hasipek M; Jiang D; Tiwari AD; Grabowski DR; Pagliuca S; Kongkiatkamon S; Patel B; Singh S; Parker Y; LaFramboise T; Lindner D; Sekeres MA; Mian OY; Saunthararajah Y; Maciejewski JP; Jha BK
    J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 35085104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Natural Flavonoid Compound Deguelin Inhibits HCMV Lytic Replication within Fibroblasts.
    Nukui M; O'Connor CM; Murphy EA
    Viruses; 2018 Nov; 10(11):. PubMed ID: 30405048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of ganciclovir-resistant human cytomegalovirus replication by Kampo (Japanese herbal medicine).
    Murayama T; Yamaguchi N; Iwamoto K; Eizuru Y
    Antivir Chem Chemother; 2006; 17(1):11-6. PubMed ID: 16542001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eltrombopag inhibits Type I interferon-mediated antiviral signaling by decreasing cellular iron.
    Ma S; Liu A; Hu X; Feng Q; Zhang Y; Li N; Peng J; Sheng Z
    Biochem Pharmacol; 2021 Apr; 186():114436. PubMed ID: 33539815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Cytomegalovirus Replication with Extended-Half-Life Synthetic Ozonides.
    Wang Y; Mukhopadhyay R; Roy S; Kapoor A; Su YP; Charman SA; Chen G; Wu J; Wang X; Vennerstrom JL; Arav-Boger R
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function.
    Erhardt JA; Erickson-Miller CL; Aivado M; Abboud M; Pillarisetti K; Toomey JR
    Exp Hematol; 2009 Sep; 37(9):1030-7. PubMed ID: 19631713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repurposing the thrombopoietin receptor agonist eltrombopag as an anticryptococcal agent.
    Ko HT; Hsu LH; Yang SY; Chen YL
    Med Mycol; 2020 Jun; 58(4):493-504. PubMed ID: 31297540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD0084430: a non-nucleoside inhibitor of human cytomegalovirus replication in vitro.
    Meyer AL; Bruening EE; Dunkle WE; Booth RJ; Steinbaugh BA; Vara Prasad JV
    Antiviral Res; 2001 Dec; 52(3):289-300. PubMed ID: 11675146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Artemisinin Derivative Artemisone Is a Potent Inhibitor of Human Cytomegalovirus Replication.
    Oiknine-Djian E; Weisblum Y; Panet A; Wong HN; Haynes RK; Wolf DG
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29712656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron chelating properties of Eltrombopag: Investigating its role in thalassemia-induced osteoporosis.
    Punzo F; Tortora C; Argenziano M; Casale M; Perrotta S; Rossi F
    PLoS One; 2018; 13(12):e0208102. PubMed ID: 30507954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombopoietin receptor agonists protect human cardiac myocytes from injury by activation of cell survival pathways.
    Baker JE; Su J; Koprowski S; Dhanasekaran A; Aufderheide TP; Gross GJ
    J Pharmacol Exp Ther; 2015 Mar; 352(3):429-37. PubMed ID: 25512369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-Acetylpyridine 5-[(dimethylamino)thiocarbonyl]-thiocarbonohydrazone (1110U81) potently inhibits human cytomegalovirus replication and potentiates the antiviral effects of ganciclovir.
    Hamzeh FM; Spector T; Lietman PS
    Antimicrob Agents Chemother; 1993 Mar; 37(3):602-4. PubMed ID: 8384821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma.
    Jeong JY; Levine MS; Abayasekara N; Berliner N; Laubach J; Vanasse GJ
    J Hematol Oncol; 2015 Apr; 8():37. PubMed ID: 25886818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist.
    Erickson-Miller CL; Delorme E; Tian SS; Hopson CB; Landis AJ; Valoret EI; Sellers TS; Rosen J; Miller SG; Luengo JI; Duffy KJ; Jenkins JM
    Stem Cells; 2009 Feb; 27(2):424-30. PubMed ID: 19038790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.